EUVIMEDEUVIMED entdecken
Open Access

TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression

Nianke Zang, Jinfeng Gan, Ye Chen, Zheng Huang, Chichu Xie, Junlong Dang, Changyuan Huang, Linjie Yang, Xuelian Chen, Guangli Rong, Jianbo Sun, Yiming Shao und 4 weitere

Cancer Communications · 2026

DOI: 10.34133/cancomm.0021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2026. Verfasst von Nianke Zang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Interferon Regulatory Factors, Melanoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

T-LAK cell-originated protein kinase (TOPK), a serine/threonine kinase, is aberrantly overexpressed in human tumors and promotes malignant proliferation. Melanoma is a highly immunogenic tumor in which CD8 + T cell-mediated cytotoxicity is usually less effective in tumor control and responsive to immune checkpoint blockade. It is unclear whether the expression and functional characterization of TOPK within the immune cells affect the tumor microenvironment (TME) in patients with melanoma. This study aims to elucidate the expression pattern and immunoregulatory function of TOPK in CD8 + T lymphocytes during antitumor responses.

Methods

Public single-cell RNA-sequencing (scRNA-seq) dataset analysis and flow cytometry assessed TOPK in tumor-infiltrating CD8 + T cells from patients with melanoma. Genetic deletion and pharmacological inhibition of TOPK using HI-TOPK-032 tested T cell-mediated melanoma control. Flow cytometry and tumor cell coculture killing assays measured effector release and target-cell apoptosis. Mechanistic analyses included assessment of interferon regulatory factor 5 (IRF5) expression, together with combination therapy using a programmed cell death protein 1 (PD-1)-blocking antibody in vivo. scRNA-seq of tumor-infiltrating lymphocytes (TILs) from Topk fl/fl and Cd8 Cre Topk fl/fl mice was also performed to define TOPK-dependent immune programs within the melanoma TME.

Results

Single-cell transcriptomes identified a TOPK + subset of tumor-infiltrating CD8 + T cells in melanoma, which was higher than that in normal lymph nodes (LNs), and exhibited suppressed cytotoxic and cytokine programs. CD8 + T cell-specific Topk deletion increased granzyme B (GzmB), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) secretion and improved tumor control. TOPK-deficient CD8 + T cells showed elevated activation-associated signaling pathways and immune effector gene expression. In murine TIL scRNA-seq, Cd8 Cre Topk fl/fl tumors exhibited increased effector and activation programs, reduced exhaustion and dysfunction programs, and enhanced immune crosstalk in the TME. Mechanistically, TOPK suppressed IRF5 expression and HI-TOPK-032 restored CD8 + T cell cytotoxicity in vitro and, with anti-PD-1, further inhibited tumor growth and increased intratumoral cytokine production. In human CD8 + T cells, enforced TOPK expression impaired cytotoxicity and cytokine secretion, reversed by IRF5 coexpression.

Conclusions

These findings establish TOPK as the immune checkpoint limiting CD8 + T cell functionality in tumors and indicate the potential of TOPK inhibition as a strategy to augment T cell-based immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesInterferon Regulatory FactorsMelanomaAnimalsMiceHumansCell Line, TumorTumor MicroenvironmentLymphocytes, Tumor-InfiltratingFemaleMitogen-Activated Protein Kinase Kinases

Substanzen

Interferon Regulatory FactorsPDZ-binding kinaseIrf5 protein, mouseMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Clinical Research Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
  • Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, P. R. China.
  • Guangxi Health Commission Key Laboratory of Tumor Immunology and Receptor-Targeted Drug Basic Research, Guilin Medical University, Guilin, Guangxi, P. R. China.
  • Department of Immunology, School of Cell and Gene Therapy, Songjiang Institute and Songjiang Hospital Affiliated to the Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.
  • Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, P. R. China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zang, N., Gan, J., Chen, Y., Huang, Z., Xie, C., Dang, J., Huang, C., Yang, L., Chen, X., Rong, G., Sun, J., Shao, Y., Wang, J., Qi, G., Liu, Y., & Zheng, S. G. (2026). TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression. Cancer Communications. https://doi.org/10.34133/cancomm.0021

Vancouver

Zang N, Gan J, Chen Y, Huang Z, Xie C, Dang J, et al. TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression. Cancer Communications. 2026. doi:10.34133/cancomm.0021

BibTeX
@article{Zang2026,
  author = {Zang, Nianke and Gan, Jinfeng and Chen, Ye and Huang, Zheng and Xie, Chichu and Dang, Junlong and Huang, Changyuan and Yang, Linjie and Chen, Xuelian and Rong, Guangli and Sun, Jianbo and Shao, Yiming and Wang, Julie and Qi, Guangying and Liu, Yu and Zheng, Song Guo},
  title = {TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression},
  journal = {Cancer Communications},
  year = {2026},
  doi = {10.34133/cancomm.0021}
}
Kostenlos starten →